Stock Track | Relay Therapeutics Soars 6.77% in Pre-Market on Strong Q4 Earnings Beat and Upcoming Milestones

Stock Track02-27

Relay Therapeutics' stock surged 6.77% during pre-market trading on Friday, following the release of its fourth quarter 2025 financial results that significantly exceeded analyst expectations.

The clinical-stage precision medicine company reported Q4 revenue of $7 million, beating the consensus estimate of $4.97 million. Additionally, Relay Therapeutics posted a narrower-than-expected net loss of $54.89 million compared to the estimated $68.1 million loss, with adjusted earnings per share of -$0.32 surpassing the -$0.42 forecast.

Investors responded positively to the company's strong cash position of $554.5 million, which provides a runway into 2029, and upcoming 2026 milestones for its lead program zovegalisib, including Phase 1/2 breast cancer data presentation at ESMO TAT in March and initial Phase 1 data in vascular anomalies expected in the first half of the year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1146128216?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 13:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1146128216","market":"sg","top_or_hot":-1,"title":"Stock Track | Relay Therapeutics Soars 6.77% in Pre-Market on Strong Q4 Earnings Beat and Upcoming Milestones","media":"Stock Track","content":"<p>Relay Therapeutics' stock surged 6.77% during pre-market trading on Friday, following the release of its fourth quarter 2025 financial results that significantly exceeded analyst expectations.</p><p>The clinical-stage precision medicine company reported Q4 revenue of $7 million, beating the consensus estimate of $4.97 million. Additionally, Relay Therapeutics posted a narrower-than-expected net loss of $54.89 million compared to the estimated $68.1 million loss, with adjusted earnings per share of -$0.32 surpassing the -$0.42 forecast.</p><p>Investors responded positively to the company's strong cash position of $554.5 million, which provides a runway into 2029, and upcoming 2026 milestones for its lead program zovegalisib, including Phase 1/2 breast cancer data presentation at ESMO TAT in March and initial Phase 1 data in vascular anomalies expected in the first half of the year.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Relay Therapeutics Soars 6.77% in Pre-Market on Strong Q4 Earnings Beat and Upcoming Milestones</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Relay Therapeutics Soars 6.77% in Pre-Market on Strong Q4 Earnings Beat and Upcoming Milestones\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-27 13:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Relay Therapeutics' stock surged 6.77% during pre-market trading on Friday, following the release of its fourth quarter 2025 financial results that significantly exceeded analyst expectations.</p><p>The clinical-stage precision medicine company reported Q4 revenue of $7 million, beating the consensus estimate of $4.97 million. Additionally, Relay Therapeutics posted a narrower-than-expected net loss of $54.89 million compared to the estimated $68.1 million loss, with adjusted earnings per share of -$0.32 surpassing the -$0.42 forecast.</p><p>Investors responded positively to the company's strong cash position of $554.5 million, which provides a runway into 2029, and upcoming 2026 milestones for its lead program zovegalisib, including Phase 1/2 breast cancer data presentation at ESMO TAT in March and initial Phase 1 data in vascular anomalies expected in the first half of the year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RLAY","symbol_name":"Relay Therapeutics","start_time":0,"source_url":"","article_id":"1146128216","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1146128216","pubTimestamp":1772170987,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Relay Therapeutics' stock surged 6.77% during pre-market trading on Friday, following the release of its fourth quarter 2025 financial results that significantly exceeded analyst expectations.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RLAY":"Relay Therapeutics"},"translate_title":"个股追踪|Relay Therapeutics盘前飙升6.77%，因第四季度盈利强劲增长和即将到来的里程碑","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RLAY":1},"content_text":"Relay Therapeutics' stock surged 6.77% during pre-market trading on Friday, following the release of its fourth quarter 2025 financial results that significantly exceeded analyst expectations.The clinical-stage precision medicine company reported Q4 revenue of $7 million, beating the consensus estimate of $4.97 million. Additionally, Relay Therapeutics posted a narrower-than-expected net loss of $54.89 million compared to the estimated $68.1 million loss, with adjusted earnings per share of -$0.32 surpassing the -$0.42 forecast.Investors responded positively to the company's strong cash position of $554.5 million, which provides a runway into 2029, and upcoming 2026 milestones for its lead program zovegalisib, including Phase 1/2 breast cancer data presentation at ESMO TAT in March and initial Phase 1 data in vascular anomalies expected in the first half of the year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1146128216","isCrawlerRequest":true}